ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2025
Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Metabolic Disorders and Inflammatory Bowel Diseases: Unraveling Shared Pathways and Clinical Interactions.Metabolites · 2026Review
- Pharmacomicrobiomics in metabolic syndrome and type 2 diabetes: the microbiome-drug-host triad.Frontiers in pharmacology · 2026Review
- Probiotic drug interactions in ulcerative colitis: a microbiota and metabolite perspective.Frontiers in microbiology · 2026Review
- The interaction between gut microbiota and host DNA methylation in the pathogenesis and therapy of inflammatory bowel disease.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The interplay between inflammatory bowel disease pharmacotherapies and the gut microbiota is increasingly recognized as a pivotal factor influencing treatment efficacy and patient outcomes. This review provides a comprehensive and up-to-date synthesis of the bidirectional interactions between inflammatory bowel disease drugs and gut microbiota, emphasizing the emerging field of pharmacomicrobiomics and associated therapeutic implications. Emerging evidence reveals that microbial composition and function not only shape drug metabolism, bioavailability, and efficacy, but are themselves profoundly altered by pharmacologic interventions. In addition to traditional oral drugs and biological therapy used in inflammatory bowel disease, recent approvals of Janus kinase inhibitors, sphingosine-1-phosphate receptor modulators as well as late-stage developmental drugs indicate that drug-microbiota interactions may increase in prominence. Understanding these intricate interactions offers significant potential: microbial signatures may help guide therapeutic decisions as companion diagnostic tools, helping clinicians predict the therapeutic outcome. Moreover, targeted manipulation of the microbiota may open entirely new avenues to complement and enhance the effectiveness of established inflammatory bowel disease therapies. By illuminating current knowledge, knowledge gaps, and future research directions, this review underscores the potential of integrating pharmacomicrobiomic insights into the next generation of personalized inflammatory bowel disease care.
Indexed as
Identifiers
41044468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.